Myelodysplastic Syndromes | Topics

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24, 2021

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.

GTB-3550 TriKE Safely Drives NK Cell Function in MDS, AML
December 08, 2020

Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

FDA Grants Breakthrough Therapy Designation to Magrolimab for Treatment of MDS
September 16, 2020

The FDA granted breakthrough therapy designation to magrolimab for the treatment of newly diagnosed myelodysplastic syndrome.